GENE News and Press, Genetic Technologies Ltd From 04/19/22

AA, BDN, CCI, CSX, CVNA, EFX, FR, GENE, GL, KALU, KMI, KNX, LBRT, LRCX, LSTR, MMLP, RLI, SAND, SEIC, SLG, SNBR, STLD, THC, TSLA, UAL, UMPQ, VMI, WHR For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Wednesday's close

Genetic Technologies (NASDAQ:GENE) reported YTD results for the nine months ended March 31. The Australian company said YTD growth in revenue was +475%. Cash receipts of A$2M in Q3, an increase of 9% on the prior quarter, and mainly comprised of EasyDNA product sales. The company noted i...

MELBOURNE, Australia, April 08, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, ASX: GTG) (“GENE” or the “Company”), a global leader in genomics-based tests in health, wellness and serious disease provides its year to date results for the nin...

Genetic Technologies Ltd (NASDAQ:GENE) traded today at a new 52-week high of $10.30. So far today approximately 121.9 million shares have been exchanged, as compared to an average 30-day volume of 65,000 shares. There is potential upside of 87.4% for shares of Genetic Technologies Ltd ba...

MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce the granting of US Patent No: ...

MELBOURNE, Australia, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce that on February 17, 2022 th...

Genetec Delivers Its Best Quarter to Date BANGI, Malaysia, Jan 26, 2022 - (ACN Newswire) - Technology leader in providing fully customised, intelligent manufacturing automation solutions, Genetec Technology Berhad announced their best financial quarter to date for their third ...

MELBOURNE, Australia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, ‘Company’, ‘GENE’, ‘geneType’), a diversified Genomics and AI driven preventative health business, provides its results for the quarter end...

Genetic Technologies (NASDAQ:GENE) expects cash receipts for Q2 of A$1.8M, a 112% increase sequentially following the integration of EasyDNA. In the coming quarters, the focus will be on further leveraging the acquisition by including the Multi-Test product. Multi-Test technical validation su...

Forecast 2QFY22 1 cash receipts +112% versus the prior quarter (1QFY22) to A$1.8 million following the completed integration of EasyDNA in the quarter Multi-Test technical validation complete and submitted to NATA 2 and CMS 3 for final regulatory approval ahead of the co...